Lymphatic pumping failure in the arm precedes dermal backflow and breast cancer-related lymphedema

手臂淋巴泵功能障碍先于真皮淋巴回流和乳腺癌相关性淋巴水肿发生。

阅读:2

Abstract

BACKGROUND: Breast cancer patients who undergo regional nodal irradiation therapy (RNI) following neoadjuvant chemotherapy and mastectomy or lumpectomy with axillary lymph node dissection (ALND) frequently encounter breast cancer-related lymphedema (BCRL). Early detection and treatment can significantly improve outcomes. Previously, near-infrared fluorescence lymphatic imaging (NIRF-LI) detection of dermal backflow, or retrograde lymphatic flow into initial lymphatics, was shown to precede clinical BCRL diagnosis by 8–23 months. Herein, we hypothesize that lymphatic pump failure is responsible for dermal backflow and may be a target to prevent onset of BCRL symptoms. METHODS: Arm lymphatics in 51 patients with locally advanced breast cancer were visualized with NIRF-LI in a prospective, longitudinal, observational clinical cohort study. Lymphatic pumping frequencies were measured to investigate pumping changes during and after breast cancer treatment. Lymphatic pumping was quantified at five timepoints: after neoadjuvant chemotherapy, but before breast cancer excision and ALND, again at four weeks post-ALND, and at 6, 12, and 18 months post-RNI. Repeated measures mixed-effects analysis was used to compare the mean pumping frequencies amongst all time points. Additionally, pairwise comparisons between any two time points were performed using Wilcoxon matched-pairs signed rank test. RESULTS: As time lapsed after surgical treatment and RNI, ipsilateral dorsal forearm, ipsilateral ventral forearm, and ventral axilla pumping failure preceded the appearance of dermal backflow and clinically diagnosed BCRL, suggesting that lymphatic pumping dysfunction is the first step in BCRL development. CONCLUSIONS: This study suggests that impairment of the intrinsic lymph pump may be responsible for the onset of clinical BCRL symptoms, and therefore represents a target for prevention of cancer-acquired lymphedema. Future research is needed to understand the molecular determinants of the intrinsic lymphatic pump, and how cancer treatments and interventions can impact them. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-026-02231-w.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。